Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Radiation Oncology
•
Myelodysplastic Syndromes
•
Hematology
What are your current recommendations for treatment of symptomatic splenomegaly in the setting of myelofibrosis when splenectomy is not an option?
Is there a preferred low dose splenic irradiation regimine?
Answer from: Radiation Oncologist at Academic Institution
I use low dose, typically 50cGy per fraction for 4-6 fractions, done in 2 fractions per week; need to check platelets each week during course.
Sign In
or
Register
to read more
881
Related Questions
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
Would involved site radiation therapy be recommended in a patient with POEMS syndrome whose myelopathy symptoms worsened after one cycle of CyBorD?
Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?
Could patients with smIPI > 1 and poor tolerability to RCHOP be offered ISRT after 3 cycles of RCHOP if interim PET showed 5-PS 1-3 response?
How would you manage a young patient with Sjogrens disease with extranodal marginal zone lymphoma involving bilateral parotid glands with bilateral cervical lymphadenopathy?
How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
How would you manage a solitary, painful, lytic bony lesion in a patient with negative PET/CT but bone marrow biopsy confirmation of multiple myeloma?
Should other treatment options be considered for MALT lymphoma if the lacrimal gland will be included in the radiation field in a patient with Sjögren's disease?
How do you approach imetelstat therapy in MDS patients with baseline neutropenia or thrombocytopenia?